Stockscreener 앱 받기
6.975
4.97%
-0.365
전일 마감가:
$7.34
열려 있는:
$7.34
하루 거래량:
330.68K
Relative Volume:
1.00
시가총액:
$492.09M
수익:
$555.06M
순이익/손실:
$-39.48M
주가수익비율:
-11.62
EPS:
-0.6
순현금흐름:
$29.05M
1주 성능:
-6.12%
1개월 성능:
-16.27%
6개월 성능:
-39.24%
1년 성능:
+75.69%
1일 변동 폭
$6.91
$7.34
1주일 범위
$6.91
$7.62
52주 변동 폭
$3.9518
$14.38
Bioventus Inc Stock (BVS) Company Profile
명칭
Bioventus Inc
전화
(919) 474-6700
주소
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
BVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
6.98 | 492.09M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
132.37 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.65 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.78 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.52 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.47 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-17 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-07 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2022-11-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-11-09 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2022-03-15 | 개시 | Craig Hallum | Buy |
| 2021-11-15 | 재개 | Morgan Stanley | Overweight |
| 2021-11-10 | 재개 | JP Morgan | Overweight |
| 2021-07-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-08 | 개시 | Canaccord Genuity | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | JP Morgan | Overweight |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioventus Inc 주식(BVS)의 최신 뉴스
Bioventus Inc (BVS) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
Legal & General Group Plc Raises Position in Bioventus Inc. (NYSE:BVS) - Defense World
Orthobiologics Market Growth Statistics & Future Prospects | Medtronic, Orthofix Medical, Bioventus - openPR.com
Bioventus Q1 2025 Earnings Preview: Key Metrics and Business Updates Coming May 6 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
LPL Financial LLC Has $433,000 Stock Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
Alliancebernstein L.P. Sells 3,500 Shares of Bioventus Inc. (NYSE:BVS) - Defense World
SEC Form DEFA14A filed by Bioventus Inc. - Quantisnow
Bioventus Inc. (NASDAQ:BVS) On The Verge Of Breaking Even - Yahoo Finance
Bioventus SVP Katrina Church sells shares for $9,712 - Investing.com Australia
Bioventus CFO Singleton sells $29,333 in stock - Investing.com Australia
Bioventus SVP Katrina Church sells shares for $9,712 By Investing.com - Investing.com South Africa
Bioventus CFO Singleton sells $29,333 in stock By Investing.com - Investing.com South Africa
Bioventus SVP sells shares worth $22,392 By Investing.com - Investing.com India
Bioventus SVP sells shares worth $22,392 - Investing.com
Bioventus Executives Sell Shares to Cover Taxes - TradingView
Bioventus Inc. (NYSE:BVS) Shares Acquired by Vanguard Group Inc. - Defense World
KLP Kapitalforvaltning AS Acquires Shares of 7,100 Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus ($BVS) Is Paying a $15.2M Settlement to Investors — Here’s How to Get Your Share - TradingView
Intramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market Insights - GlobeNewswire Inc.
Commonwealth Equity Services LLC Raises Stock Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus Inc.'s (NASDAQ:BVS) institutional investors lost 9.6% over the past week but have profited from longer-term gains - simplywall.st
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
HighTower Advisors LLC Increases Position in Bioventus Inc. (NYSE:BVS) - Defense World
(BVS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Ensign Group Invests in Growth With New Facility Acquisitions - TradingView
Canaccord maintains Bioventus stock with $15 target, bullish outlook By Investing.com - Investing.com Australia
Canaccord maintains Bioventus stock with $15 target, bullish outlook - Investing.com
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Bone Growth Stimulator Market Is Booming Worldwide | Orthofix Medical Inc., Medtronic, Zimmer Biomet, Bioventus Inc - openPR.com
Charles Schwab Investment Management Inc. Grows Position in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus CFO Mark Leonard sells $53,639 in stock By Investing.com - Investing.com Australia
Bioventus CFO Mark Leonard sells $53,639 in stock - Investing.com India
(BVS) Proactive Strategies - news.stocktradersdaily.com
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates - MSN
Bioventus SVP Katrina Church sells shares worth $9,925 By Investing.com - Investing.com Australia
Bioventus SVP Anthony D’Adamio sells $25,496 in stock - Investing.com India
Bioventus SVP Katrina Church sells shares worth $9,925 - Investing.com India
Europe Viscosupplementation Market Projected To Witness Substantial Growth, 2025-2032: Sanofi S.A., Bioventus - EIN News
Bioventus (NYSE:BVS) Receives “Buy” Rating from Canaccord Genuity Group - Defense World
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
How To Trade (BVS) - news.stocktradersdaily.com
Earnings call transcript: Bioventus Q4 2024 beats revenue forecast, stock surges - Investing.com Australia
Bioventus Earnings Call: Strong Growth & 2025 Outlook - TipRanks
Bioventus Inc. (NASDAQ:BVS) Q4 2024 Earnings Call Transcript - Insider Monkey
Bioventus: Strong Financial Performance and Strategic Growth Drive Buy Rating - TipRanks
Bioventus Full Year 2024 Earnings: Beats Expectations - Yahoo
Bioventus Faces Potential Stock Dilution Risk Amid Resale of 35 Million Shares - TipRanks
Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ... - Yahoo Finance
Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Bioventus Inc (BVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.06%
0.20%
자본화:
|
볼륨(24시간):